Contrary to expectations, neuroimaging shows psychedelics reduce total brain activity. However, they simultaneously increase connectivity between disparate brain regions that don't normally communicate. This "rewiring" is correlated with therapeutic outcomes, such as unpairing negative mood states from self-perception networks.

The core innovation of psychedelics isn't just the mechanism but the treatment paradigm. By offering a rapid, acute treatment that doesn't require chronic medication, they could allow patients to get better and return to their lives, avoiding long-term entanglement with the mental health system and reducing stigma.

A key hurdle in psychedelic trials is that patients often know if they received the active drug. The industry is addressing this "functional unblinding" by aiming for therapeutic effects so large in Phase 3 that they significantly outweigh any potential placebo bias, making the unblinding issue less critical for approval.

Amid dozens of successful studies, one of the only psychedelic trials to report a negative result provides a compelling control case. The trial administered psychedelics to patients inside a claustrophobic, noisy MRI scanner with no psychological support, suggesting a hostile environment can completely negate the drug's therapeutic potential.

The business model for psychedelic medicine hinges on clinic time. Long-acting drugs like psilocybin or LSD require an 8-hour session, creating a logistical and cost burden. Therapies with shorter experiences, like DMT's 30-minute window, offer a significant advantage in patient convenience and clinic throughput.

While Compass's psilocybin shows strong Phase 3 data, its 6-8 hour in-office administration is a major commercial hurdle compared to J&J's Spravato (2 hours). The key investment thesis is that its significantly longer-lasting effect will justify the logistical complexity for patients, providers, and payers.

For the next wave of psychedelic therapies, the pivotal regulatory question is treatment durability. The FDA's view on "as-needed" (PRN) dosing versus the fixed-interval schedule of approved drugs like Spravato will determine the commercial viability and clinical pathway for companies like Compass Pathways.

The future market for psychedelic therapies will not be monolithic. Companies are developing drugs that cater to different patient desires, such as the length of the clinical session (a few hours vs. six) and the intensity of the hallucinogenic experience (from a full 'trip' to avoiding it entirely), creating distinct market segments.

The long duration (4-6+ hours) of first-generation psychedelics like psilocybin creates a major commercial bottleneck for clinics. Atai's focus on shorter, two-hour compounds is a strategic bet on scalability, allowing clinics to treat more patients per day and reducing the exhaustion of monitoring staff.